Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial

Lancet

Volumn 364, Issue 9444, 2004, Pages 1505-1512

  Israel, Elliot ^a   Chinchilli, Vernon M ^b   Ford, Jean G ^c   Boushey, Homer A ^d   Cherniack, Reuben ^e   Craig, Timothy J ^b   Deykin, Aaron ^a   Fagan, Joanne K ^c   Fahy, John V ^d   Fish, James ^f   Kraft, Monica ^e   Kunselman, Susan J ^b   Lazarus, Stephen C ^d   Lemanske Jr , Robert F ^g   Liggett, Stephen B ^h   Martin, Richard J ^e   Mitra, Nandita ^a   Peters, Stephen P ^f   Silverman, Eric ^a   Sorkness, Christine A ^g   Szefler, Stanley J ^e   Wechsler, Michael E ^a   Weiss, Scott T ^a   Drazen, Jeffrey M ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXPIRATORY FLOW RATE; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 6944232728     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17273-5     Document Type: Article

References (23)

1. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 327:1992;1420-1425
2. National Asthma Education Program. Guidelines for the diagnosis and treatment of asthma II. 1997;National Institutes of Health, Bethesda, MD
3. National Asthma Education and Prevention Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma, update on selected topics, 2002. J Allergy Clin Immunol. 110:2002;S141-S218
4. National Heart Lung and Blood Institute. NHLBI/WHO Workshop Report: Global strategy for asthma management and prevention. Global Initiative for Asthma. Bethesda, MD: National Heart Lung and Blood Institute. Publication #95-3659 1995.
5. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 336:1990;1391-1396
6. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax. 48:1993;134
7. 2-agonist treatment. Am Rev Respir Dis. 148:1993;707-712
8. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med. 335:1996;841-847
9. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet. 355:2000;1675-1679
10. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 33:1994;9414-9419
11. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 162:2000;75-80
12. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 55:2000;762-767
13. Martin RJ, Kephart DK, Dyer AM, Fahy J, Kraft M. Quality control within the Asthma Clinical Research Network. Controlled Clin Trials. 22:2001;S207-S221
14. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 100:1997;3184-3188
15. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol. 16:1998;1347-1351
16. Weir TD, Mallek N, Sandford AJ, et al. Beta 2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med. 158:1998;787-791
17. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 94:1994;676-683
18. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 325:1991;388-392
19. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 97:2000;10483-10488
20. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 268:1993;23116-23121
21. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta(2)-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 13:1995;25-33
22. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq-receptor signaling via phospholipase-C underlies the airway beta-agonist paradox. J Clin Invest. 112:2003;619-626
23. Shore SA, Drazen JM. Beta-agonists and asthma: too much of a good thing? J Clin Invest. 112:2003;495-497